JANSSEN RESEARCH & DEVELOPMENT, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Determine Frequency of DNA-repair Defects in Men With Metastatic Prostate Cancer

Completed

Conditions: Metastatic Prostate Cancer

Interventions: Other: Saliva, Blood, or and/or Archival Tumor Tissue Collection and Analysis

First Posted Date: 2019-03-12

Last Posted Date: 2023-12-11

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 14532

Registration Number: NCT03871816

Locations: 🇺🇸
Sansum Clinic Pharm, Santa Barbara, California, United States
🇺🇸
Central Care Cancer Center, Bolivar, Missouri, United States
🇧🇪
Jolimont, Haine-Saint-Paul, La Louviere, Belgium

and more 332 locations

Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab

Phase 2

Terminated

Conditions: Multiple Myeloma

Interventions: Drug: Carfilzomib 20 mg/m^2
Drug: Carfilzomib 70 mg/m^2
Drug: Dexamethasone 40 mg
Drug: Dexamethasone 20 mg
Drug: Dara-SC 1800 mg

First Posted Date: 2019-03-12

Last Posted Date: 2023-12-19

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 88

Registration Number: NCT03871829

Locations: 🇳🇱
Zuyderland Medical Center, Sittard, Netherlands
🇬🇷
University General Hospital of Rio, Patra, Greece
🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States

and more 105 locations

A Study of (14C) Radiolabeled JNJ-56136379 in Healthy Male Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: 14C-JNJ-56136379

First Posted Date: 2019-03-06

Last Posted Date: 2019-08-07

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 6

Registration Number: NCT03864601

Locations: 🇺🇸
Covance Clinical Research Unit, Madison, Wisconsin, United States

A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Pregnant Women at High Risk for Early Onset Severe Hemolytic Disease of the Fetus and Newborn (HDFN)

Phase 2

Completed

Conditions: Hemolytic Disease of the Fetus and Newborn

Interventions: Drug: M281

First Posted Date: 2019-02-15

Last Posted Date: 2025-01-09

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 14

Registration Number: NCT03842189

Locations: 🇺🇸
University of Texas Health Science Center, Houston, Texas, United States
🇺🇸
University of Cincinnati, Cincinnati, Ohio, United States
🇦🇺
Liverpool Hospital, Sydney, Australia

and more 16 locations

Pre-Approval Access to Pimodivir for the Treatment of Patients With H7N9 Influenza A Infection

Conditions: H7N9 Subtype of Influenza A Virus

First Posted Date: 2019-02-08

Last Posted Date: 2020-10-28

Lead Sponsor: Janssen Research & Development, LLC

Registration Number: NCT03834376

Pre-Approval Access to Esketamine Nasal Spray for the Treatment of Treatment-Resistant Depression (TRD)

Conditions: Depressive Disorder, Treatment-Resistant

First Posted Date: 2019-02-04

Last Posted Date: 2020-02-10

Lead Sponsor: Janssen Research & Development, LLC

Registration Number: NCT03829579

A Study of Three Different Doses of VAC52416 (ExPEC10V) in Adults Aged 60 to 85 Years in Stable Health

Phase 1

Active, not recruiting

Conditions: Extraintestinal Pathogenic Escherichia Coli Prevention

Interventions: Biological: ExPEC10V
Biological: ExPEC4V
Biological: Prevnar 13
Biological: Placebo

First Posted Date: 2019-01-28

Last Posted Date: 2024-12-10

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 836

Registration Number: NCT03819049

Locations: 🇺🇸
Qps-Mra, Llc, Miami, Florida, United States
🇺🇸
Optimal Research, Peoria, Illinois, United States
🇺🇸
Synexus Clinical Research US Inc, Columbus, Ohio, United States

and more 20 locations

A Study to Investigate the Different Modes of (S) Ketamine Administration in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: (S)-ketamine IV Infusion
Drug: (S)-ketamine Oral Thin Film
Drug: Placebo

First Posted Date: 2019-01-17

Last Posted Date: 2019-09-12

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 96

Registration Number: NCT03808259

Locations: 🇧🇪
Clinical Pharmacology Unit, Merksem, Belgium

A Study of Apalutamide Administered Orally as Whole Tablets and as a Mixture in Applesauce in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Apalutamide

First Posted Date: 2019-01-14

Last Posted Date: 2020-08-10

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 12

Registration Number: NCT03802682

Locations: 🇧🇪
Clinical Pharmacology Unit, Merksem, Belgium

A Study to Assess the Drug-Drug Interaction Between Bedaquiline and Clarithromycin in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Bedaquiline
Drug: Clarithromycin

First Posted Date: 2019-01-11

Last Posted Date: 2019-08-28

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 16

Registration Number: NCT03800550

Locations: 🇧🇪
SGS Life Science Services, Antwerpen, Belgium

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy